Rimonabant is a selective cannabinoid CB1 receptor antagonist previously utilized as an anorectic anti-obesity drug to assist in weight management and smoking cessation. Although historically withdrawn… Read more
Rimonabant is a selective cannabinoid CB1 receptor antagonist previously utilized as an anorectic anti-obesity drug to assist in weight management and smoking cessation. Although historically withdrawn from clinical use due to psychiatric side effects, it continues to be significant in pharmaceutical research and development. The category of rimonabant products includes the active pharmaceutical ingredient, its related impurities, and specialized metabolites. Additionally, these offerings comprise stable isotope-labelled compounds, such as deuterium-labelled analogues, which are essential for conducting precise quantitative analysis, mass spectrometry, and impurity profiling. Pharmaceutical laboratories rely on these high-quality reference standards for method validation and comprehensive quality control procedures, ensuring rigorous identification and quantification during analytical investigations of this drug substance and its degradation pathways.